Theolytics
Theolytics uses its ADENOVO discovery platform to develop oncolytic viral therapies designed to selectively kill cancer cells and activate the immune system against solid tumors. The company's lead program focuses on creating a novel treatment for ovarian cancer. Their approach combines virology, bioinformatics, and molecular biology to identify therapies optimized for specific patient populations.
Biotech
Oncology
Immunotherapy
Funding summary
- Total raised
- €5.5M
- Funding rounds
- 2
Investors in Theolytics
Investors on record for Theolytics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Theolytics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors